 | |
| Clinical data | |
|---|---|
| Other names | 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C22H32Cl2N2O4 |
| Molar mass | 459.41 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
 
(what is this?)
(verify) | |
Lorglumide (CR-1409) is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a cholecystokinin antagonist, [1] with fairly high selectivity for the CCKA subtype. [2] It has been suggested as a potential treatment for a variety of gastrointestinal problems including stomach ulcers, irritable bowel syndrome, dyspepsia, constipation and pancreatitis, as well as some forms of cancer, but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research. [3] [4] [5] [6]
References
- ^ Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, et al. (November 1987). "Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists". Arzneimittel-Forschung. 37 (11): 1265–8. PMID 3440035.
- ^ González-Puga C, García-Navarro A, Escames G, León J, López-Cantarero M, Ros E, Acuña-Castroviejo D (October 2005). "Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin". Journal of Pineal Research. 39 (3): 243–50. doi: 10.1111/j.1600-079X.2005.00239.x. PMID 16150104. S2CID 20187767.
- ^ de Tullio P, Delarge J, Pirotte B (June 1999). "Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists)". Current Medicinal Chemistry. 6 (6): 433–55. doi: 10.2174/0929867306666220330183253. PMID 10213792. S2CID 6031554.
- ^ de Tullio P, Delarge J, Pirotte B (January 2000). "Therapeutic and chemical developments of cholecystokinin receptor ligands". Expert Opinion on Investigational Drugs. 9 (1): 129–46. doi: 10.1517/13543784.9.1.129. PMID 11060666. S2CID 39985897.
- ^ Herranz R (September 2003). "Cholecystokinin antagonists: pharmacological and therapeutic potential". Medicinal Research Reviews. 23 (5): 559–605. doi: 10.1002/med.10042. PMID 12789687. S2CID 45758560.
- ^ Berna MJ, Tapia JA, Sancho V, Jensen RT (December 2007). "Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential". Current Opinion in Pharmacology. 7 (6): 583–92. doi: 10.1016/j.coph.2007.09.011. PMC 2186776. PMID 17997137.
|
| |
| Clinical data | |
|---|---|
| Other names | 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C22H32Cl2N2O4 |
| Molar mass | 459.41 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
|
(what is this?)
(verify) | |
Lorglumide (CR-1409) is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a cholecystokinin antagonist, [1] with fairly high selectivity for the CCKA subtype. [2] It has been suggested as a potential treatment for a variety of gastrointestinal problems including stomach ulcers, irritable bowel syndrome, dyspepsia, constipation and pancreatitis, as well as some forms of cancer, but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research. [3] [4] [5] [6]
References
- ^ Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, et al. (November 1987). "Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists". Arzneimittel-Forschung. 37 (11): 1265–8. PMID 3440035.
- ^ González-Puga C, García-Navarro A, Escames G, León J, López-Cantarero M, Ros E, Acuña-Castroviejo D (October 2005). "Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin". Journal of Pineal Research. 39 (3): 243–50. doi: 10.1111/j.1600-079X.2005.00239.x. PMID 16150104. S2CID 20187767.
- ^ de Tullio P, Delarge J, Pirotte B (June 1999). "Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists)". Current Medicinal Chemistry. 6 (6): 433–55. doi: 10.2174/0929867306666220330183253. PMID 10213792. S2CID 6031554.
- ^ de Tullio P, Delarge J, Pirotte B (January 2000). "Therapeutic and chemical developments of cholecystokinin receptor ligands". Expert Opinion on Investigational Drugs. 9 (1): 129–46. doi: 10.1517/13543784.9.1.129. PMID 11060666. S2CID 39985897.
- ^ Herranz R (September 2003). "Cholecystokinin antagonists: pharmacological and therapeutic potential". Medicinal Research Reviews. 23 (5): 559–605. doi: 10.1002/med.10042. PMID 12789687. S2CID 45758560.
- ^ Berna MJ, Tapia JA, Sancho V, Jensen RT (December 2007). "Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential". Current Opinion in Pharmacology. 7 (6): 583–92. doi: 10.1016/j.coph.2007.09.011. PMC 2186776. PMID 17997137.